MHRA authorises Daiichi Sankyo quizartinib for AML for marketing
2024-03-12
上市批准临床3期临床结果
Preview
来源: Pharmaceutical Technology
Daiichi Sankyo’s quizartinib is indicated for use as a first-line treatment in adults with acute myeloid leukaemia. Credit: Nemes Laszlo / Shutterstock.com.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Daiichi Sankyo for quizartinib (Vanflyta) for use as a first-line treatment in adults with acute myeloid leukaemia (AML) with a FLT3-ITD mutation.
The decision allows for the oral administration of quizartinib in combination with chemotherapy – a significant development in the treatment of AML.
Taken once daily, quizartinib targets tyrosine kinases to hinder the growth of abnormal bone marrow cells.
The treatment duration and dosage are determined by the prescribing physician and may continue post-chemotherapy.
The approval is backed by a double-blind, randomised, placebo-controlled Phase III clinical trial in 539 adult subjects aged between 18 and 75 years with newly diagnosed FLT3-ITD positive AML.
See Also:
MHRA approves Marinus’ ganaxolone for CDKL5 deficiency disorderCDKL5 deficiency disorder
Preview
来源: Pharmaceutical Technology
Preview
来源: Pharmaceutical Technology
The study demonstrated a statistically significant improvement in overall survival (time from randomisation to death from any cause) for patients who received quizartinib.
Patients receiving quizartinib had a median overall survival of 31.9 months compared to 15.1 months for those receiving a placebo.
Abnormal liver enzymes, low blood platelet and white blood cell levels, anaemia, diarrhoea, nausea, stomach pain and headache were the most common side effects linked to the trial.
MHRA Healthcare Quality and Access interim executive director Julian Beach stated: “Our key priorities are keeping patients safe and enabling their access to high quality, safe and effective medical products.
“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all medicines, we will keep its safety under close review.”
In another development, the MHRA also gave marketing authorisation to Pfizer for etrasimod (Velsipity) for the treatment of moderately to severely active ulcerative colitis.
Etrasimod is prescribed as a long-term treatment and should be initiated only under a doctor’s supervision.
The UK National Institute for Health and Care Excellence (NICE) has also published a final guidance recommending etrasimod for ulcerative colitis.
With the NICE recommendation, more than 25,000 people in England will be eligible to receive the treatment.
The latest development comes after the MHRA approved Marinus Pharmaceuticals’ ganaxolone, marketed as Ztalmy, an anti-seizure medication for cyclin-dependent kinase-like 5 (CDLK5) deficiency disordercyclin-dependent kinase-like 5 (CDLK5) deficiency disorder.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。